CD28 and CD4+/CD56+ hematodermic neoplasm: The preclinical activity of anti-CD123 CAR T cells has been demonstrated in BPDCN, where it selectively kills tumor cells mainly through antigen-specific T cell-mediated cytotoxicity.[55–57] Bole-Richard et al[58] demonstrated that third-generation CD28/4-1BB CD123 CAR T cells can significantly exert anti-BPDCN efficacy by effectively reducing BPDCN blast burden in vivo and eliminating autologous BPDCN blasts in vitro.